Oramed Pharmaceuticl (ORMP) 4.58 $ORMP
Oramed to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual BIO CEO & Investor Conference, taking place February 9-10, 2015 in New York City. Dr. Michael Berelowitz, Chairman of the Scientific Advisory Board of Oramed, will present a corporate overview on February 10, 2015.
ORMP: 4.58 (+0.16)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals Inc. Issues Letter to Shareholders
PR Newswire - Wed Jan 28, 8:00AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com),
ORMP: 4.58 (+0.16)
Oramed Granted Patent in Israel for Oral Administration of GLP-1
PR Newswire - Fri Jan 16, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Israel Patent Office has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."
ORMP: 4.58 (+0.16)
Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 16, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LNCO: 12.30 (+0.28), ORMP: 4.58 (+0.16), INFI: 15.13 (+0.55), LINE: 12.94 (+0.40), ORPN: 7.17 (+0.04), JAXB: 10.50 (unch), CLMT: 25.38 (+0.32), OBAS: 6.25 (-0.05)
Oramed snags $5M investment from Chinese pharma
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:04AM CST
ORMP: 4.58 (+0.16)
Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company
PR Newswire - Wed Dec 03, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014, for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014, in a private placement.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014
PR Newswire - Mon Dec 01, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Michael Berelowitz, M.D., Director and Chairman of the Scientific Advisory Board of Oramed, will present a corporate overview on Tuesday, December 2, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ORMP: 4.58 (+0.16)
Coverage Initiation Report Focuses on Oramed Pharmaceuticals
Marketwired - Tue Nov 11, 7:45AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.
ORMP: 4.58 (+0.16)
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Fri Oct 31, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.
ORMP: 4.58 (+0.16)
Oramed to Present at the FireRock Annual Micro-Cap Conference
PR Newswire - Fri Oct 24, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes
M2 - Wed Oct 22, 10:39AM CDT
Oramed Pharmaceuticals Inc (NASDAQCM: ORMP), a clinical-stage pharmaceutical company that developms oral drug delivery systems, announce on Wednesday that its Phase IIa clinical trial of ORMD-0801, its proprietary oral insulin capsules to treat type 1 diabetes, has achieved positive top-line clinical results.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Wed Oct 22, 7:29AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
ORMP: 4.58 (+0.16)
Oramed to Present at Family Office & Wealth Management Conference
PR Newswire - Mon Sep 15, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference.
ORMP: 4.58 (+0.16)
Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval
ACCESSWIRE - Thu Sep 11, 7:01AM CDT
Los Angeles, CA / September 11, 2014 / Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an onerous side effect profile that rivals medications like Bristol-Myers Squibb's (BMY:NYSE) anti-blood clot drug Plavix which has caused internal bleeding that results in vomiting coagulated blood. Medicine for diabetics, one of the largest populations of sick patients in the US, should look to more natural means for bringing insulin into the body. Oramed Pharmaceuticals, Inc. (ORMP:NASDAQ) offers a potential remedy and has been making good progress in clinical trials, as outlined below.
ORMP: 4.58 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Oramed to Present at Upcoming Conferences
PR Newswire - Wed Sep 03, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at the following conferences in September 2014:
ORMP: 4.58 (+0.16)
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 43.76 (+0.61), ORMP: 4.58 (+0.16), TTHI: 6.67 (-0.07), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
Oramed Granted Patent in Spain for Oral Administration of Insulin
PR Newswire - Tue Aug 19, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
ORMP: 4.58 (+0.16)
Oramed to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual BIO CEO & Investor Conference, taking place February 9-10, 2015 in New York City. Dr. Michael Berelowitz, Chairman of the Scientific Advisory Board of Oramed, will present a corporate overview on February 10, 2015.
ORMP: 4.58 (+0.16)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals Inc. Issues Letter to Shareholders
PR Newswire - Wed Jan 28, 8:00AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com),
ORMP: 4.58 (+0.16)
Oramed Granted Patent in Israel for Oral Administration of GLP-1
PR Newswire - Fri Jan 16, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Israel Patent Office has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."
ORMP: 4.58 (+0.16)
Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 16, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LNCO: 12.30 (+0.28), ORMP: 4.58 (+0.16), INFI: 15.13 (+0.55), LINE: 12.94 (+0.40), ORPN: 7.17 (+0.04), JAXB: 10.50 (unch), CLMT: 25.38 (+0.32), OBAS: 6.25 (-0.05)
Oramed snags $5M investment from Chinese pharma
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:04AM CST
ORMP: 4.58 (+0.16)
Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company
PR Newswire - Wed Dec 03, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014, for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014, in a private placement.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014
PR Newswire - Mon Dec 01, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Michael Berelowitz, M.D., Director and Chairman of the Scientific Advisory Board of Oramed, will present a corporate overview on Tuesday, December 2, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ORMP: 4.58 (+0.16)
Coverage Initiation Report Focuses on Oramed Pharmaceuticals
Marketwired - Tue Nov 11, 7:45AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.
ORMP: 4.58 (+0.16)
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Fri Oct 31, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.
ORMP: 4.58 (+0.16)
Oramed to Present at the FireRock Annual Micro-Cap Conference
PR Newswire - Fri Oct 24, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes
M2 - Wed Oct 22, 10:39AM CDT
Oramed Pharmaceuticals Inc (NASDAQCM: ORMP), a clinical-stage pharmaceutical company that developms oral drug delivery systems, announce on Wednesday that its Phase IIa clinical trial of ORMD-0801, its proprietary oral insulin capsules to treat type 1 diabetes, has achieved positive top-line clinical results.
ORMP: 4.58 (+0.16)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Wed Oct 22, 7:29AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
ORMP: 4.58 (+0.16)
Oramed to Present at Family Office & Wealth Management Conference
PR Newswire - Mon Sep 15, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference.
ORMP: 4.58 (+0.16)
Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval
ACCESSWIRE - Thu Sep 11, 7:01AM CDT
Los Angeles, CA / September 11, 2014 / Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an onerous side effect profile that rivals medications like Bristol-Myers Squibb's (BMY:NYSE) anti-blood clot drug Plavix which has caused internal bleeding that results in vomiting coagulated blood. Medicine for diabetics, one of the largest populations of sick patients in the US, should look to more natural means for bringing insulin into the body. Oramed Pharmaceuticals, Inc. (ORMP:NASDAQ) offers a potential remedy and has been making good progress in clinical trials, as outlined below.
ORMP: 4.58 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Oramed to Present at Upcoming Conferences
PR Newswire - Wed Sep 03, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at the following conferences in September 2014:
ORMP: 4.58 (+0.16)
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 43.76 (+0.61), ORMP: 4.58 (+0.16), TTHI: 6.67 (-0.07), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
Oramed Granted Patent in Spain for Oral Administration of Insulin
PR Newswire - Tue Aug 19, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
ORMP: 4.58 (+0.16)
